4/A: Clover Health GC Amends Stock Ownership Filing

Clover Health's General Counsel, Karen Soares, amended her beneficial ownership filing to reflect the full achievement and vesting of performance-based restricted stock units.

Summary

• This filing is an amendment to a previously filed Form 4 for Karen Soares, General Counsel and Secretary of Clover Health Investments, Corp.
• On September 13, 2024, 518,000 Class A Common Stock restricted stock units (RSUs) were acquired, representing the full achievement of performance-based vesting conditions from an October 31, 2023 grant.
• One-half of these earned RSUs vested and settled on September 13, 2024, with the remaining half scheduled to vest on October 31, 2025.
• On July 31, 2025, 38,086 Class A Common Stock shares were disposed of at $2.89 per share to cover tax obligations related to the vesting of time-based RSUs.
• Following these transactions through July 31, 2025, Karen Soares' direct beneficial ownership of Class A Common Stock totals 1,476,946 shares.

Sentiment

Score: 7

Explanation: The filing indicates that performance targets for a significant RSU grant were met, leading to the vesting of 518,000 shares for the General Counsel. This suggests positive internal performance metrics were achieved. The subsequent disposal of shares for tax purposes is a routine event.

Positives

• Achievement of performance targets for a significant grant of 518,000 restricted stock units (RSUs) for the General Counsel, indicating successful attainment of internal company goals.
• The vesting of a substantial number of shares for an executive aligns executive incentives with shareholder value.

Negatives

• No specific negative operational or financial information is disclosed in this filing. The disposal of shares for tax purposes is a routine event and not indicative of negative sentiment.

Future Outlook

The filing indicates future vesting events for remaining restricted stock units, with the next vesting of performance-based RSUs scheduled for October 31, 2025, and the final vesting of time-based RSUs also on October 31, 2025, subject to continued employment.

Industry Context

This filing is specific to an individual insider's stock transactions and does not provide broader industry context or trends.

Comparison to Industry Standards

• Not applicable as this filing details individual insider stock transactions rather than company-wide financial or operational results.

Stakeholder Impact

• Shareholders: Minor dilution from RSU issuance, but reflects executive compensation structure and achievement of performance targets.
• Reporting Person: Increased direct ownership of company stock, aligning personal incentives with company performance.

Next Steps

• Remaining one-half of performance-based restricted stock units (RSUs) are scheduled to vest on October 31, 2025.
• Final vesting of remaining time-based restricted stock units (RSUs) is scheduled for October 31, 2025.

Key Dates

Recommendation

The filing details routine insider stock transactions related to executive compensation and the achievement of performance targets for restricted stock units. While the meeting of performance targets is a positive signal regarding internal company performance, this filing alone does not provide sufficient new operational or financial data to warrant a strong buy or sell recommendation. It confirms the execution of a pre-determined compensation plan.

Keywords

Clover Health, CLOV, SEC filing, Form 4, insider trading, restricted stock units, RSU, beneficial ownership, executive compensation